Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2024-11-18 Capital/Financing Update
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
4DMedical wins 3 year commercial contract with UCSD Health 2 pages 196.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 19 November 2024 about 4DMedical signing a three-year commercial contract with UC San Diego Health. It is a corporate news release focusing on a commercial contract win, describing the significance and potential impact of the contract. There are no financial statements, no detailed financial performance data, no regulatory filings, no voting results, no management or board changes, no legal proceedings, and no earnings or interim report data. The document is a straightforward commercial update about a contract win, which fits best under Capital/Financing Update (CAP) as it relates to business development and commercial contracts that can impact company capital or revenue streams. The document length is about 4752 characters, which is consistent with a typical announcement rather than a full report. Therefore, the most appropriate classification is CAP with high confidence.
2024-11-18 English
Application for quotation of securities - 4DX 9 pages 22.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance and quotation of securities under an employee incentive scheme, including the number of securities, issue date, and other listing rule compliance information. This type of document is a formal announcement related to capital changes, specifically the quotation of new shares or securities. It is not a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, as it deals with new securities being quoted and issued. The document length and content confirm it is not a brief notice but a detailed application for quotation, consistent with the SHA category.
2024-11-14 English
Application for quotation of securities - 4DX 11 pages 29.4KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from 4DMedical Limited regarding the application for quotation of securities issued under an employee incentive scheme. It details the number and type of securities to be quoted, issue dates, and other listing rule requirements. The document is a formal application to the ASX for the quotation of new securities, which is a capital market activity related to share issuance and listing. It is not a financial report, earnings release, or management discussion. It is also not a regulatory filing or announcement of a report publication. The content fits the category of announcements regarding new share issues or capital changes, specifically the quotation of securities. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length and detail support a high confidence in this classification.
2024-11-07 English
Notification regarding unquoted securities - 4DX 9 pages 23.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and contains detailed information about the issuance of unquoted securities under an employee incentive scheme, including performance rights and options. It includes specifics such as security codes, issue dates, numbers of securities issued, and mentions key management personnel involved. The document is a formal notification to the ASX (Australian Securities Exchange) about these securities issuances. This type of document corresponds to announcements related to share issues or capital changes rather than a full financial report or other categories. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (8133 characters) and content confirm it is a full notification rather than a brief announcement or a report publication announcement.
2024-10-31 English
Quarterly Activity Report and Appendix 4C for Q1 FY2025 12 pages 808.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activity Report and Appendix 4C for Q1 FY2025' and dated 31 October 2024. It contains detailed financial performance data for the quarter ended 30 September 2024, including operating revenue, cash balances, and cash flow information. It also discusses operational highlights, commercial agreements, clinical studies, and market expansion activities. The presence of substantive financial data and analysis for a fiscal quarter, along with operational commentary, aligns with the characteristics of an Interim / Quarterly Report (IR). The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2025
2024-10-30 English
4DMedical wins $1.9m funding for CT VQ clinical studies 3 pages 238.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 October 2024, detailing a $1.9 million non-dilutive funding award to 4DMedical for clinical studies related to their CT:VQ technology. The content focuses on the grant details, clinical trial plans, and the technology's potential impact. There are no financial statements, quarterly or annual results, or detailed financial performance data. The document is a corporate announcement about funding and clinical study progress rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital/Financing Update since it is not about fundraising through equity or debt but a government grant. It is not a Management Report or Investor Presentation as it lacks detailed financial analysis or strategic presentation format. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about funding and clinical study progress that does not fit other specific categories.
2024-10-22 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.